FTC eyes new approach to pharmaceutical mergers

The Federal Trade Commission (FTC) is eyeing a tougher approach to its review of pharmaceutical mergers.

The commission said in a statement Tuesday it is launching a working group with domestic and international agencies to “identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.”